As mentioned above, mutant in tissue is widely used to predict intrinsic resistance to anti-EGFR antibodies in patients with metastatic CRC
As mentioned above, mutant in tissue is widely used to predict intrinsic resistance to anti-EGFR antibodies in patients with metastatic CRC. serial measurements. Furthermore, blood should provide a more complete profile of mutations present in heterogeneous tumours than a single-needle tissue biopsy. A limitation of blood vis–vis tissue, however, is lower sensitivity and, thus, the possibility of missing an actionable mutation. Despite this limitation, blood-based predictive biomarkers, such as mutant for predicting response to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer and mutant for predicting response to alpelisib in combination with fulvestrant in advanced breast cancer, may be used when tissue is usually unavailable. Although tissue remains the gold standard for detecting predictive biomarkers, it is likely that several further blood-based assays will soon be validated and used when tissue is usually unavailable or unsuitable for analysis. for Predicting Response to EGFR TKIs in Patients with Non-Small-Cell Lung Cancer The first ctDNA predictive biomarker/companion diagnostic to enter clinical use involved mutational analysis of for the identification of patients with NSCLC that were likely to benefit from EGFR tyrosine kinase inhibitors (TKIs) [30,31,32]. Activating (also known as sensitising) mutations somatic mutations are present in 15C25% of Caucasian subjects and in 35C50% of East-Asian patients with untreated NSCLC [30,31,32]. Approximately 90% of these mutations involve an in-frame deletion in exon 19 (codons 746C750) or ORY-1001 (RG-6016) an L858R point mutation in exon 21. Less frequent mutations include G719X (4%), L861X (1%), S768I (1%) mutations, and exon 20 insertions (2%). These mutations, especially the in-frame deletion in exon 19 and L858R, alter the structure of the ATP ORY-1001 (RG-6016) binding pocket in the tyrosine kinase domain name of EGFR, leading to ligand-independent activation. This in turn results in increased RAS-RAF-MAPK signalling, which ultimately drives the growth TEAD4 ORY-1001 (RG-6016) and progression of NSCLC. Since mutant is usually a driver gene for a subset of NSCLC, several TKI were developed to target the corresponding mutant protein. Currently, at least five clinically approved (US FDA) EGFR TKI are available, gefitinib, erlotinib (first generation), afatinib and dacominitib (second generation) and osimertinib (third generation) [32]. Gefitinib, erlotinib and afatinib are selective for sensitising mutation such as the in-frame deletion in exon 19 or L858R point mutations in exon 21, while osimertinib is usually selective for both the sensitising mutations and T790M resistance mutation (see below). Since these compounds possess higher affinity than the natural kinase substrate, ATP for the ATP-binding pocket in EGFR, they competitively inhibit the tyrosine kinase activity of the mutant receptor, thus blocking downstream signalling which in turn leads to inhibition of tumour cell growth. Several randomised phase III trials have now shown that treatment of NSCLC patients with advanced disease possessing sensitising mutations using first- or second-generation TKIs resulted in superior response rates, enhanced progression-free survival, reduced toxicities and increased quality of life compared to standard chemotherapy (for review, see recommendations [30,31,32,33]). Recently, the third generation TKI inhibitor, osimertinib was shown to enhance overall survival compared with gefitinib or erlotinib (hazard ratio (HR) for death, 0.80; 95.0% CI, 0.64 to 1 1.00; = 0.046) [34]. Based on this obtaining, joint guidelines recently published by the American Society of Clinical Oncology (ASCO) and Ontario Health (OH) stated that where available, osimertinib should be the optimal first-line ORY-1001 (RG-6016) treatment for NSCLC patients with sensitising mutations [35]. Based on the early clinical results with first generation TKIs, tissue mutation analysis of entered clinical use for selecting patients with metastatic NSCLC likely to benefit from these drugs. However, as mentioned above, the use of tissue has several limitations, many of which can be largely overcome by analysing ctDNA. Overall, strong ORY-1001 (RG-6016) concordance (70C90%) is found between the presence of activating mutations in tumour tissue and matching ctDNA [36,37,38,39,40]. Thus, following a meta-analysis of 27 studies involving 4000 patients, the pooled sensitivity, specificity and areas under the curve for ctDNA versus tissue were 60%, 94%, and 0.9208 for the detection of mutations. For detecting exon 19 deletions, the corresponding values were 64%, 99%, and 0.9583 and for detecting L858R mutations, values were 57%, 99%, and 0.9605, respectively [36]. In a more recent prospective study involving 180 patients with advanced NSCLC, ctDNA had a specificity of 100% for both 19 del and L858R mutation [37]. The sensitivity of ctDNA however, was 82% for 19 del and 74% for L858R. For a commercial ctDNA mutation assay approved by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), i.e., Cobas (Roche Molecular Systems) (see below), the ctDNA assay exhibited a specificity of 98.2% and a sensitivity of 76.7% for the detection of both the exon 19del and L858R mutations [38]..